Dexcel Pharma Technologies Ltd. - 10 Nov 2022 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
10%+ Owner
Signature
/s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman
Issuer symbol
ROIV
Transactions as of
10 Nov 2022
Transactions value $
$20,000,000
Form type
4
Filing time
14 Nov 2022, 07:40:35 UTC
Previous filing
26 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Purchase $20M +4M +4.05% $5.00 103M 10 Nov 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 4,684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.
F2 The common shares were purchased by Dexcel in a registered public offering on November 10, 2022.